Fondazione San Raffaele del Monte Tabor
Latest From Fondazione San Raffaele del Monte Tabor
There are still many lessons to be learned in commercializing cell and gene therapies. Experts in the industry discussed challenges and best practices at the Alliance for Regenerative Medicine's annual meeting in October.
Alexion’s “hotly contested” purchase of Enobia last December didn’t get much attention, but it marked a watershed year for rare disease drug deals. Will high drug prices, skittish regulators and a gold-rush push by Big Pharma start to sour the sector?
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.